Detalles de la búsqueda
1.
The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
Arthritis Res Ther
; 24(1): 46, 2022 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35172878
2.
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
Arthritis Rheumatol
; 74(1): 112-123, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34164944
3.
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
Arthritis Care Res (Hoboken)
; 74(11): 1822-1828, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35439360
4.
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.
Lupus Sci Med
; 8(1)2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33568389
5.
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
RMD Open
; 7(3)2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34531304
6.
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial.
Lancet Rheumatol
; 3(2): e122-e130, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38279368
7.
The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
Arthritis Res Ther
; 22(1): 102, 2020 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32366280
Resultados
1 -
7
de 7
1
Próxima >
>>